
Heart Arrhythmia After COVID-19 Vaccine: A Very Rare Side Effect
Arrhythmia is not a known side effect of COVID-19 vaccines. But ongoing monitoring has shown rare instances of heart complications in people who have received the Pfizer-BioNTech or Moderna mRNA vaccines.
Arrhythmia affects the rate or rhythm at which the heart beats. Your heart might beat too fast (tachycardia), too slow (bradycardia), too early (premature contraction), or erratically (fibrillation).
Arrhythmia can also be a sign of myocarditis, or inflammation of the heart muscle. Myocarditis is a very rare side effect of Pfizer-BioNTech or Moderna mRNA COVID-19 vaccines.
You're more likely to experience arrhythmia or myocarditis caused by COVID-19 itself than from the COVID-19 vaccine.
At least 2 out of every 10 people hospitalized with COVID-19 experience heart problems, including damage to their heart muscle and arrhythmia. This is what scientists mean when they say the benefits of vaccination outweigh the risks.
Keep reading to learn more about heart arrhythmia and myocarditis following COVID-19 vaccination.
What the research says
Data from the Centers for Disease Control and Prevention (CDC) shows that higher than normal cases of heart inflammation have been reported in the United States after COVID-19 vaccination with the Pfizer-BioNTech or Moderna vaccines.
These heart issues occurred mostly in males between ages 12 and 39 after they received the second dose of the vaccine, usually within a few days of receiving the vaccine. This side effect hasn't been observed in people who received the Johnson & Johnson vaccine or the Novavax protein subunit vaccine.
The Pfizer-BioNTech and Moderna vaccines are messenger RNA (mRNA) vaccines. These vaccines contain genetically engineered mRNA that teaches your cells how to create antibodies capable of fighting the coronavirus that causes COVID-19.
Traditional vaccines, like the Johnson & Johnson COVID-19 vaccine, contain genetic material from the virus, which also helps your body create antibodies.
A 2021 analysis of CDC data found that people ages 12 to 39 who received their second COVID-19 mRNA vaccine had about a 13 in 1 million chance of experiencing heart inflammation. In other words, this side effect is exceedingly rare.
Another 2021 study involved people ages 16 and up who were vaccinated against COVID-19. It also found slightly increased risks of heart inflammation after participants' first and second doses of COVID-19 vaccines in the first 28 days after vaccination. This research included the Oxford-AstraZeneca vaccine as well as the Pfizer-BioNTech and Moderna vaccines.
This risk of myocarditis did appear to be a bit higher after a second dose of the Moderna vaccine — not the other vaccines studied — and was only observed in people younger than 40.
Vaccination for people with preexisting heart conditions
Even though arrhythmias are sometimes associated with myocarditis, no direct association was found between arrhythmia and COVID-19 vaccination.
The American Heart Association recommends that anyone with heart disease get vaccinated against COVID-19 as soon as possible. This is because they're at a much greater risk of heart-related complications from the coronavirus than they are from any COVID-19 vaccine.
However, if you or your child has experienced myocarditis after a vaccine before, discuss your options with your doctor before getting vaccinated.
What are the symptoms of heart arrhythmia?
Arrhythmia doesn't always cause symptoms — that's why you'll sometimes hear it called 'asymptomatic.'
But possible symptoms can include:
chest pain
shortness of breath
feeling like the heart is fluttering or pounding (palpitations)
rapid heartbeat
slow or irregular heartbeat
A 2021 study suggests that most people suspected to have myocarditis after COVID-19 experienced chest pain about 2 or 3 days after the second dose of a COVID-19 mRNA vaccine.
Arrhythmia during COVID-19
Arrhythmias are more often seen after developing COVID-19 than after vaccination.
In small studies conducted in Wuhan, China, during the initial outbreak of COVID-19, arrhythmias occurred at a rate of 16.7% of people hospitalized with COVID-19, with 44.4% of those who were hospitalized being treated in the intensive care unit (ICU).
A retrospective 2021 study of 3,970 COVID-19 admissions at Mount Sinai Hospital in New York City found that atrial fibrillation and atrial flutter (AF/AFL) happened in 10% of study participants. AF/AFL was also associated with a 46% higher risk of death — compared with 26% of study participants who had no arrhythmias.
Viral infection is the most common cause of inflammation in the heart muscle in children. Children who develop myocarditis after COVID-19 also typically experience a more severe case than if it happens after a COVID-19 vaccination.
Heart complications can occur even after you recover from COVID-19.
Common vaccine side effects
Heart problems are a very rare side effect of COVID-19 vaccines.
More common side effects are mild and temporary, including:
fever
pain and soreness at injection site
fatigue
headache
chills
body aches
These side effects occur as the vaccine triggers a response from your immune system. In other words, these side effects mean the vaccine is doing its job.
Is the COVID-19 vaccine still effective?
When first studied in earlier coronavirus variants, COVID-19 vaccines were shown to be roughly:
95% effective at preventing coronavirus infection
94% effective at preventing COVID-19 hospitalizations and deaths among fully vaccinated adults
Yet viruses constantly change. Several new variants have emerged since the novel coronavirus first appeared.
But even though the first COVID-19 vaccines aren't as effective at preventing infection by the Delta or Omicron variants, they offer significant protection against these variants by reducing your risk of:
severe illness
hospitalization
death
Research published in 2022 estimates that COVID-19 vaccines are still up to 90% effective at preventing severe outcomes of COVID-19, including the need for invasive mechanical ventilation or death.
People who are fully vaccinated and received a third booster had the highest level of protection against severe disease and hospitalization. Newer boosters have since been developed.
Who should get a COVID-19 vaccine?
Under the new administration, the CDC recommends that most people ages 18 years and older get an annual COVID-19 vaccine, while those 6 months to 17 years old and pregnant people make a personal decision with their loved ones.
However, the American Academy of Pediatrics (AAP) recommends vaccination for every child 6 months or older, and the American College of Obstetricians and Gynecologists (ACOG) recommends vaccination for all pregnant people.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Forbes
12 minutes ago
- Forbes
Men Are Claiming Ozempic, GLP-1 Meds Are Making Their Genitals Bigger
Some men have been asserting on social media that their penises have grown larger since they started ... More taking GLP-1 agonist medications. This has been dubbed Ozempic penis. But are such claims supported by scientific evidence in any way? (Photo: Getty) You could say that taking Ozempic and other glucagon-like peptide-1 agonists for weight loss has been a growing trend. But recent claims on social media and Internet forums seem to be taking such a statement to another level, as in a genital level. Yep, as a Reddit thread shows, some men have been asserting that their penises have grown larger since they started taking GLP-1 agonist medications. Some have been dubbing this perceived growth 'Ozempic penis.' There are big questions, though, about the legitimacy and accuracy of such claims. After all, 'accuracy' isn't always the first word you may think of when it comes to men and what they say about their penis sizes. Here are some examples of the lengths to which members of Reddit have been going to describe what GLP-1 agonists supposedly did to their members. An anonymous Redditor said, 'I recently measured myself down there and noticed I gained about one inch. Now I think people will say it was because of the fat loss. However, at the time I measured myself before (4 years ago), I was thinner.' Another anonymous Redditor went on even longer: 'I gained 1.5 inches in length. No joke. Like you I obviously know how long I was before I got very fat. Then after about seven months on Tirzepatide in my case I gained 1.5 inches in length. Definitely not all from weight loss.' Of course, posts were from anonymous Redditors are the same as verified data or a peer-reviewed scientific study. Something posted on an Internet forum or social media can be like something written on the wall of toilet stall in a public restroom. Neither of the aforementioned Redditors provided any clear evidence supporting their claims. Of course, when some random guy comments about his penis, others may not be that inclined to say, 'Show us some proof.' Moreover, accurately measuring penis length can be in the words of Run-DMC tricky. If you want different measurements over time to be comparable, you've got to use the exact same landmarks consistently. The formal definition of penis length is measuring from the true base of the penis all the way to the tip. And if you are using a tape measure, you shouldn't give it some slack. It should be held taut. Plus, measurements should be done when the penis is fully erect. That's because of the whole 'grower' versus 'shower' continuum. A so-called 'grower' is someone whose penis gets significantly longer and maybe even wider when going from flaccid to erect whereas a so-called 'shower' doesn't undergo any such major change between the two states. The former can bring more of a surprise, while with the latter, what you already see at any time is essentially what you get. Whether you are a grower versus a shower depends on the elasticity of the tissue in your penis, the amount of collagen in your penis and blood flow to the penis. Therefore, different measurements done at different degrees of erection could yield very different measurements. Remember all erections are not created equal. There are scales ranging from 0 to 4 and 0 to 10 to rate the firmness and rigidity of an erection, which can vary significantly by excitement, stimulation and other factors beyond you and your partner's control. And you could say that it is hard to always achieve the hardest possible erection. Despite the Redditors' claims otherwise, weight loss is still the leading possibility behind these perceived increases in penis length. It's important to remember that your penis is attached to your pelvis, at least it should be attached, and that the border between where your penis ends and the rest of the pelvis begins is not necessarily clear. Therefore, the amount of fat in the pelvis around the pubic area can affect the length of the penis that is visible and readily measurable. On top of that, the GLP-1 agonists seem to be causing striking fat loss in different parts of the body that many people may not be used to seeing. That's given rise to terms like 'Ozempic finger' and 'Wegovy butt' and 'Ozempic mouth' and Ozempic feet" as I have covered in Forbes previously. So, if someone gained weight and then started taking GLP-1 agonist medications, the end result result may not be exactly what that person looked like previously. When you lose weight, another thing that can improve is blood flow to different parts of your body, including your penis. And blood flowing into the penis and staying in there are what results in and maintains erections. The greater the blood flow, the more erect and rigid the penis. So, there is the possibility that more rigid erections are being misinterpreted at longer penile length. On the flip side, some on Reddit have complained of erectile dysfunction after starting GLP-1 agonists. As it stands now, ED is not an established side effect of such medications. But more studies may be needed to get a better sense of the range of possible side effects of Ozempic and other such medications over longer periods of time and in broader populations than those in the original clinical trials. If you do notice a change in penis size in either direction, don't simply say, 'Yay' or 'Them's the breaks.' It could be a sign of a significant underlying problem. Growth in genital size could be a sign of a growth like a tumor or fluid accumulation. Decrease in genital size could be ED, which could be a sign of cardiovascular disease or other blood flow problems. You may want to check your testosterone levels as well. Of course, anytime anyone claims that something can increase penis size, chances are there will be men out there who think, 'How can I get some of that?' If you are thinking of injecting yourself with Ozempic or some other GLP-1 agonist just to increase your penis size, don't. Again the long and the short of it is that claims on social media and the Internet are just not the same as peer-reviewed scientific studies.
Yahoo
23 minutes ago
- Yahoo
AffableBPM Graduates from 2025 Creative Destruction Lab (CDL) Program
Accelerating AI-Powered Automation for Healthcare Operations SEATTLE, June 16, 2025 /PRNewswire/ -- AffableBPM is proud to announce its successful graduation from the 2025 Creative Destruction Lab (CDL) program, having completed the rigorous Computational Stream at CDL-Seattle. This milestone represents a pivotal step in AffableBPM's mission to expand non-clinical process automation within the healthcare industry. CDL is one of the world's premier seed-stage programs for science and technology-based ventures. The program unites visionary entrepreneurs, experienced operators, and leading researchers to help scale high-impact startups. Selection and graduation from CDL are highly competitive, requiring companies to meet stringent performance goals and demonstrate significant potential. AffableBPM's achievements were recognized with an invitation to CDL's prestigious Super Session in Toronto on June 24-25, 2025. About AffableBPM AffableBPM is an AI-powered SaaS platform transforming operational compliance in healthcare, one of the last frontiers of digital transformation. Particularly in mid-sized hospitals and rural clinics, non-clinical back-office operations remain largely manual, while technology has advanced on the clinical side. AffableBPM unlocks this underserved market with configurable, no-code workflows that cut administrative costs, eliminate silos, and accelerate audit approvals by up to 75%, hence closes gaps to protect 35–40% of Medicare/Medicaid related provider revenue, enabling staff to focus on patient care instead of paperwork. While the platform has found strong adoption in healthcare, its modular design and AI capabilities make it scalable across other highly regulated industries. Founder's Perspective "Through the CDL program, we received invaluable guidance from top leaders in business and healthcare. The mentorship strengthened our strategy, helped validate product-market fit, and deepened our competitive edge in the increasingly complex healthcare operations landscape. Our mission is to empower business users to build and manage workflows independently, reducing IT burden. This strategy—starting with a few repeatable, pre-built healthcare-specific workflows—has proven successful, enabling us to expand as organizational needs grow." — Rajashree Varma, Founder & CEO, AffableBPM AI Innovation for Compliance Operations AffableBPM enhances healthcare teams' ability to break down data silos, streamline workflows, and elevate productivity, all while maintaining regulatory compliance. With real-time visibility, routing, and audit-ready documentation, the platform aligns with HIPAA, CFR, CMS, and Joint Commission standards. Our latest AI modules automate repetitive administrative tasks, freeing up staff to focus on high-value, human-centered care. Key AI-powered modules include : Importer Copilot – Automates classification and data extraction into structured workflows. Discovery Copilot – Enables secure, real-time data exploration expediting summary generation. Helpchat Copilot – Provides instant, chat-based answers to learn the solution for faster adoption. Insight Copilot – Delivers real-time business insights using natural language prompts. AffableBPM integrates seamlessly with enterprise systems, enabling the vision of end-to-end Agentic AI journeys. Recognized by Microsoft as an ISV Success Partner spotlight, the platform continues to scale through product innovation, partner collaboration, and customer success. A Vision for the Future At AffableBPM, our vision is to make automation effortless and accessible, especially for mid-sized healthcare systems. The CDL experience has reinforced our commitment to fast, scalable deployment of no-code configurable workflows that eliminate manual inefficiencies, reduce compliance risks, and accelerate operational excellence. We're building the future of healthcare operations—connected, compliant, and ready to grow. We extend our sincere thanks to CDL mentors Neil Jordan , Douglas Foster , Jordan Javier , T.A. McCann , Gena Cook , Buffy Alegria and the CDL community leaders like Emer Dooley and team for their support and insights that helped us grow. "AffableBPM has demonstrated how healthcare organizations can move faster and smarter by eliminating repetitive administrative burdens. The team's no-code, workflow-first approach stood out during the CDL program, and their progress over the last two years is a testament to their commitment to driving measurable outcomes for their clients and staying compliance in highly regulated vertical." Neil Jordan, Strategic Advisor, Former Microsoft Healthcare GM (Executive) "AffableBPM is solving some of healthcare's biggest challenges—manual and fragmented back-office operations. Their no-code, configurable platform empowers teams to automate faster, stay compliant, and drive consistent operational improvements. What stood out through the CDL program was their ability to scale workflows proving that their solution delivers real, repeatable value for its partner organizations." Jordan Javier, Healthcare Operational Efficiency SME and Advisor We have seen firsthand how inefficient back-office processes hurt patients and families. That's why our solution is to solve this problem—because every hour saved on admin is an hour given back to patient care. Contact us today to learn more: Sales@ For more information about AffableBPM, visit To learn more about the CDL program, visit Media Contact: Manisha Umbarje, Director of Marketing, AffableBPM Phone: 425-428-7261 | Email: AffableBPM: No-Code Configurable Workflows for Healthcare Operational Compliance View original content to download multimedia: SOURCE AffableBPM Corporation Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
Millennium Space Systems Delivers Pair of Space Vehicles to Launch Site for NASA's TRACERS Mission
EL SEGUNDO, Calif., June 16, 2025 /PRNewswire/ -- Millennium Space Systems, a Boeing Company, delivered two space vehicles for NASA's Tandem Reconnection and Cusp Electrodynamics Reconnaissance Satellites (TRACERS) mission to Vandenberg Space Force Base Friday, marking a key milestone in preparation for launch later this year. "Millennium is incredibly proud of our team and partners at the University of Iowa, Southwest Research Institute, and NASA, for reaching this milestone and getting TRACERS to the launch site," said Richard Prasad, TRACERS program manager, Millennium Space Systems. "Progressing to final integration at launch site showcases the confidence from all parties that both the TRACERS space vehicles and the Millennium Mission Operations Center (MOC) are ready for launch and the start of operations. We're all excited to see TRACERS on-orbit." The TRACERS mission will measure the connection between solar wind and the magnetic field surrounding Earth. With the completion of rigorous tests, including environmental, mechanical and systems verification, the space vehicles are now prepared to travel through Earth's polar cusp region over the north and south magnetic poles. Ultimately, the mission will enhance our understanding of space weather and its potential impacts on critical technologies such as satellites, communications networks and power grids. "Delivering TRACERS demonstrates how the same approach we use for national security missions can support cutting-edge science," said Tony Gingiss, CEO, Millennium Space Systems. "The ability to deliver high-performance spacecraft is critical, not just for advancing scientific understanding and enabling future space weather forecasting, but also, for strengthening space resilience and readiness in support of national defense objectives." The launch window is set to open in Summer 2025, with specific timing dependent on mission readiness and other logistics. About Millennium Space SystemsMillennium Space Systems, a Boeing Company, is a small satellite prime, delivering high-performance constellation solutions for National Security Space. Founded in 2001, the company's active production lines and 80% vertical integration enable the rapid delivery of small satellites across missions and orbits – LEO, MEO and GEO. For more information, visit Media ContactMichael Atchue, Communications ManagerE-mail: View original content to download multimedia: SOURCE Millennium Space Systems Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data